The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_014336.5(AIPL1):c.1126C>T (p.Pro376Ser)

CA203312

65708 (ClinVar)

Gene: AIPL1 (HGNC:23746)
Condition: AIPL1-related retinopathy (MONDO:0100438)
Inheritance Mode: Autosomal recessive inheritance
UUID: 5a69bac5-904d-4762-be15-7e88071e00b1
Approved on: 2025-09-29
Published on: 2025-09-29

HGVS expressions

NM_014336.5:c.1126C>T
NM_014336.5(AIPL1):c.1126C>T (p.Pro376Ser)
NC_000017.11:g.6425489G>A
CM000679.2:g.6425489G>A
NC_000017.10:g.6328809G>A
CM000679.1:g.6328809G>A
NC_000017.9:g.6269533G>A
NG_008474.1:g.14711C>T
ENST00000381129.8:c.1126C>T
ENST00000250087.9:c.937C>T
ENST00000381128.2:c.*998C>T
ENST00000381129.7:c.1126C>T
ENST00000570466.5:c.1060C>T
ENST00000570584.5:c.251+8430C>T
ENST00000574506.5:c.1090C>T
ENST00000575265.5:c.*1097C>T
ENST00000576307.5:c.946C>T
ENST00000576776.5:c.1054C>T
ENST00000621374.4:c.*144C>T
NM_001033054.2:c.937C>T
NM_001033055.2:c.946C>T
NM_001285399.2:c.1090C>T
NM_001285400.2:c.1060C>T
NM_001285401.2:c.1054C>T
NM_001285402.1:c.1009C>T
NM_014336.4:c.1126C>T
NM_001033054.3:c.937C>T
NM_001033055.3:c.946C>T
NM_001285399.3:c.1090C>T
NM_001285400.3:c.1060C>T
NM_001285401.3:c.1054C>T
NM_001285402.2:c.1009C>T
NM_001285403.3:c.*1097C>T
NM_001285403.4:c.*1097C>T
More

Benign

Met criteria codes 3
BA1 BS2 BP4
Not Met criteria codes 1
BS3

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for AIPL1 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP
NM_014336.5(AIPL1):c.1126C>T (p.Pro376Ser) is a missense variant in exon 6 of 6 that is predicted to replace proline with serine at amino acid p.376. This variant is present in gnomAD v.4.1.0 at a GrpMax allele frequency of 0.06125, with 4,695 alleles / 74,822 total alleles and 166 homozygotes in the African/African American population, which is higher than the ClinGen LCA/eoRD VCEP BA1 threshold of >0.0057 (BA1). The variant has been found in the homozygous state in 170 adult individuals in gnomAD which exceeds the LCA/eoRD VCEP threshold of ≥6 (gnomAD version 4.1.0; BS2). The computational predictor REVEL gives a score of 0.129, which is below the ClinGen LCA/eoRD VCEP threshold of ≤0.183 and predicts a non-damaging effect on AIPL1 protein function. In addition, the splicing impact predictor SpliceAI gives a delta score of 0.00, which is below the ClinGen LCA/eoRD VCEP recommended threshold of <0.1 and does not predict an impact on splicing (BP4_Moderate). In summary, this variant meets the criteria to be classified as Benign for AIPL1-related retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: BA1, BS2, and BP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/24/2025).
Met criteria codes
BA1
This variant is present in gnomAD v.4.1.0 at a Grpmax allele frequency of 0.06125, with 4,695 alleles / 74,822 total alleles and 166 homozygotes in the African/African American population, which is higher than the ClinGen LCA/eoRD VCEP BA1 threshold of >0.0057 (BA1).
BS2
The variant has been found in the homozygous state in 170 adult individuals in gnomAD which exceeds the LCA/eoRD VCEP threshold of ≥6 (gnomAD version 4.1.0; BS2).
BP4
The computational predictor REVEL gives a score of 0.129, which is below the ClinGen LCA/eoRD VCEP threshold of ≤0.183 and predicts a non-damaging effect on AIPL1 protein function. In addition, the splicing impact predictor SpliceAI gives a delta score of 0.00, which is below the ClinGen LCA/eoRD VCEP recommended threshold of <0.1 and does not predict an impact on splicing (BP4_Moderate).
Not Met criteria codes
BS3
The variant exhibits similar expression relative to the wild-type AIPL1 control, and co-expression of the variant with PDE6C and Pγ resulted in cGMP hydrolysis activity equivalent to the wild-type (PMID: 33067476). The variant did not exhibit aggregation or abnormal subcellular distribution in COS-7 cells (PMID: 33067476). However, these assays are not approved to meet BS3_Supporting.

Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.